Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

Clinical trial NCT05351593 · RECRUITING

Trial details

NCT number: NCT05351593
Sponsor: James Rubenstein
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

CNS Lymphoma Primary Central Nervous System Lymphoma Secondary Central Nervous System Lymphoma

Start date: 2022-06-08
Primary completion: 2026-12-31
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.